Durable medical equipment

Lifeward Reports First Quarter 2024 Financial Results

Retrieved on: 
onsdag, maj 15, 2024
DBA, CMS, Medicare, SCI, Sale, Health, AlterG, Traction, Face, Durable medical equipment, Acquisition, Operating cost, Rehabilitation, Macs, Robotics, Disability, Home, Walking, Health insurance

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today announced its financial results for the three months ended March 31, 2024.

Key Points: 
  • Gross margin was 26.4% during the first quarter of 2024, compared to 46.4% in the first quarter of 2023.
  • Total operating expenses in the first quarter of 2024 were $7.9 million, compared to $4.9 million in the first quarter of 2023.
  • Operating loss in the first quarter of 2024 was $6.5 million, compared to $4.3 million in the first quarter of 2023.
  • Following the results of Q1’24, Lifeward continues to expect revenue of between $28 to $32 million in 2024.

Durable Medical Equipment Platforms and Partnerships Qualitative Analysis Report 2024 - ResearchAndMarkets.com

Retrieved on: 
torsdag, maj 16, 2024
Technology, Medical Supplies, Seniors, Health Technology, Professional Services, Health, Consumer, Environmental, Social and Governance (ESG), Artificial Intelligence, ESG, Investment, Prevalence, Conditional sentence, Qualitative analysis, Artificial intelligence, Marketing, Ageing, DME, Growth, Durable medical equipment, Biophysical environment, Medicine, Retail

The "Durable Medical Equipment: Platforms and Partnerships (Qualitative Analysis)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Durable Medical Equipment: Platforms and Partnerships (Qualitative Analysis)" report has been added to ResearchAndMarkets.com's offering.
  • This report analyzes the latest trends in durable medical equipment, focusing on emerging platforms, strategic partnerships, and ESG-focused innovation.
  • Durable Medical Equipment (DME) typically refers to equipment that manages basic medical or daily needs and can withstand repeated or extended use for at least three years.
  • "Durable Medical Equipment: Platforms and Partnerships (Qualitative Analysis)" Highlights:
    This report analyzes the Durable Medical Equipment (DME) market, anticipating growth driven by an aging population and the increasing prevalence of chronic diseases.

Momcozy Announces Collaboration with 1 Natural Way To Provide Accessible Breastfeeding Solutions For New Mothers

Retrieved on: 
torsdag, maj 2, 2024
Mother, Health, S12, Pregnancy, Durable medical equipment, Insurance, Partnership, M5, Birth control

This innovative collaborative partnership aims to provide mothers with easy access to free Momcozy breastfeeding equipment and accessories through insurance reimbursement facilitated by 1 Natural Way.

Key Points: 
  • This innovative collaborative partnership aims to provide mothers with easy access to free Momcozy breastfeeding equipment and accessories through insurance reimbursement facilitated by 1 Natural Way.
  • This first-ever collaboration between Momcozy + 1 Natural Way commences May 1, 2024, coinciding with the launch of 1NW's new platform.
  • These intuitively designed, mom-friendly pumps are designed to provide mothers with efficient and comfortable breastfeeding solutions.
  • This synergistic collaboration between Momcozy and 1NW represents a significant step forward in supporting maternal health and well-being for all mothers.

Medicare Revises 2024 Fee Schedule to Include Payment Rate for the ReWalk Personal Exoskeleton

Retrieved on: 
fredag, april 12, 2024
CMS, DBA, Robotics, Durable medical equipment, Patient, Physician, Face, Medicare, Rehabilitation, Disability, Health insurance

CMS states that it calculated this final payment amount by averaging pricing information for exoskeleton devices from Lifeward and other manufacturers.

Key Points: 
  • CMS states that it calculated this final payment amount by averaging pricing information for exoskeleton devices from Lifeward and other manufacturers.
  • “This CMS publication finalizes the payment rate for the ReWalk Personal Exoskeleton for 2024, which importantly concludes all open items related to establishing Medicare benefit category assignment, coding, and reimbursement,” said Larry Jasinski, CEO of Lifeward.
  • The final payment rate is in effective for Medicare claims with dates of service on or after April 1, 2024.
  • To learn more about Medicare reimbursement for Lifeward’s ReWalk Personal Exoskeleton, please visit GoLifeward.com/Medicare.

Lifeward CEO Issues Open Letter to Shareholders on Progress to Finalize Exoskeleton Medicare Payment Rate

Retrieved on: 
måndag, april 1, 2024
HCPCS, Durable medical equipment, Disability, Freedom, Face, Robotics, DBA, Macs, Medicare, CMS, SCI, Rehabilitation

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today issued an open letter from Larry Jasinski, Chief Executive Officer, to shareholders discussing the Company’s progress with the Centers for Medicare & Medicaid Services (“CMS”) to establish a payment rate for ReWalk Personal Exoskeletons. The full letter is published below:

Key Points: 
  • As a result of the deferral, the payment rate is not included in CMS’ April 2024 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (“DMEPOS”) fee schedule of Medicare payment rates that are effective April 1.
  • Our active engagement with CMS is ongoing and we work to establish the payment rate as soon as possible.
  • Until a payment rate for exoskeletons is added to the DMEPOS schedule, the Medicare Administrative Contractors (“MACs”) still have authority to approve and pay claims on a case-by-case basis with discretion to set the payment rate.
  • Lifeward intends to submit an additional 60-75 additional Medicare claims by the end of 2024 to accelerate its momentum in expanding access for qualified Medicare beneficiaries.

Neurolutions, Inc. Announces Groundbreaking CMS Decision for IpsiHand™: A Leap Forward in Stroke Rehabilitation

Retrieved on: 
tisdag, mars 12, 2024
Health, Hospitals, Neurology, Health Technology, Practice Management, Physical Therapy, HCPCS, Durable medical equipment, Brain, BCI, Patient, DME, Stroke, Classification, Survivor, Medicare, FDA, CMS, Movement, Rehabilitation, Medical device

E0738 will be used to describe “Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, including microprocessor, all components and accessories” to describe the IpsiHand Upper Extremity Rehabilitation System.

Key Points: 
  • E0738 will be used to describe “Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, including microprocessor, all components and accessories” to describe the IpsiHand Upper Extremity Rehabilitation System.
  • The IpsiHand System is a breakthrough therapeutic device and the only FDA-cleared, commercially available solution that enables non-invasive, at-home rehabilitation for stroke survivors affected by chronic motor deficits.
  • CMS’ decision also includes a final Medicare benefit category determination, classifying the IpsiHand as Durable Medical Equipment (DME).
  • Neurolutions is proud to partner with CMS to advance the forefront of the rapidly-growing frontier of BCI enabled post-stroke neurorehabilitation.

Bonafide and Synthpop announce partnership at MedTrade 2024

Retrieved on: 
tisdag, mars 26, 2024
AI, Partnership, Durable medical equipment, Patient, DME, Software, Health, HME, Medical device

DALLAS, March 26, 2024 /PRNewswire/ -- In a groundbreaking move poised to revolutionize the patient intake and resupply processes, Bonafide and Synthpop have announced a strategic partnership.

Key Points: 
  • DALLAS, March 26, 2024 /PRNewswire/ -- In a groundbreaking move poised to revolutionize the patient intake and resupply processes, Bonafide and Synthpop have announced a strategic partnership.
  • The announcement comes during MedTrade 2024, the year's most anticipated Durable Medical Equipment (DME) conference.
  • Synthpop uses advanced AI solutions to streamline workflows, making it a perfect match to enhance and scale the Bonafide product offering.
  • The announcement of this partnership at MedTrade 2024 underscores both companies' commitment to advancing healthcare technology and improving patient outcomes.

CMS awards Noridian Medicare DME contract for third time

Retrieved on: 
tisdag, mars 5, 2024
Durable medical equipment, CMS, FFS, Medicare, JD, DME, Pharmaceutical industry

FARGO, N.D., March 05, 2024 (GLOBE NEWSWIRE) -- Noridian Healthcare Solutions, LLC (Noridian) , a leader in developing solutions for federal, state and commercial health care programs, proudly announces the re-award of the Durable Medical Equipment (DME) Medicare Jurisdiction D (JD) contract.

Key Points: 
  • FARGO, N.D., March 05, 2024 (GLOBE NEWSWIRE) -- Noridian Healthcare Solutions, LLC (Noridian) , a leader in developing solutions for federal, state and commercial health care programs, proudly announces the re-award of the Durable Medical Equipment (DME) Medicare Jurisdiction D (JD) contract.
  • The Centers for Medicare & Medicaid Services (CMS) recently re-awarded Noridian the $152.8 million contract, concluding a full-and-open competitive procurement.
  • Territories, Noridian processes more than 13 million fee-for-service (FFS) claims for nearly 25,000 DME suppliers, resulting in $2.6 billion in payments for the JD contract.
  • For nearly two decades, Noridian has diligently served the suppliers and beneficiaries of JD,” said Noridian president and CEO Jon Bogenreif.

UnitedHealth Group Update on Change Healthcare Cyberattack

Retrieved on: 
fredag, mars 8, 2024
Security, Health, Technology, Practice Management, Health Insurance, Managed Care, Pharmacy, Medicine, Optum, Durable medical equipment, Electronic prescribing, Part, Change Healthcare, Manager, Medicare, Patient, Medicare Part D, UnitedHealth Group, Medicaid, Environment, Software, Health insurance

UnitedHealth Group continues to make substantial progress in mitigating the impact to consumers and care providers of the unprecedented cyberattack on the U.S. health system and the Change Healthcare claims and payment infrastructure.

Key Points: 
  • UnitedHealth Group continues to make substantial progress in mitigating the impact to consumers and care providers of the unprecedented cyberattack on the U.S. health system and the Change Healthcare claims and payment infrastructure.
  • “We are committed to providing relief for people affected by this malicious attack on the U.S. health system,” said Andrew Witty, CEO of UnitedHealth Group.
  • We’re determined to make this right as fast as possible.”
    Based on our ongoing investigation, there is no indication that any other UnitedHealth Group systems have been affected by this attack.
  • For more information and access to all solutions provided by UnitedHealth Group, visit http://www.uhg.com/changehealthcarecyberresponse .

Dexcom G7, the Smallest, Most Accurate, Easy-to-Use CGM Now Connects to the Tandem t:slim X2 Insulin Pump

Retrieved on: 
onsdag, december 6, 2023
Health, Medical Devices, Diabetes, Technology, Health Technology, Software, Biotechnology, Durable medical equipment, Insulin, Garmin, AID, Automated insulin delivery system, Risk, DXCM, CGM, Tandem Diabetes Care, Tandem, Multimedia, Pharmacy, DME, MD, Dexcom, Diabetic retinopathy, Hypoglycemia, G6, Medical device, Pharmaceutical industry, Video game, Apple, Glycated hemoglobin

View the full release here: https://www.businesswire.com/news/home/20231206143334/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231206143334/en/
    Dexcom G7 CGM now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in the U.S. (Photo: Business Wire)
    “There’s a reason Dexcom is the undisputed leader in CGM connectivity and the clear choice for AID systems,” said Jake Leach, executive vice president and chief operating officer at Dexcom.
  • Tandem t:slim X2 pumps pre-loaded with Dexcom G7 integration are now shipping to new customers.
  • To learn more and to get started with Dexcom G7 and the Tandem t:slim X2 insulin pump today, visit Dexcom.com/tandem .
  • Dexcom G7 and t:slim X2 insulin pump connectivity is expected to launch in additional countries outside the U.S. in early 2024.